Double-stranded sirna inhibiting HSD17b13 expression and conjugate thereof

WO2026233265A1PCT designated stage Publication Date: 2026-11-12ZHEJIANG YANGLI PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/094572
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-04-30
Publication Date
2026-11-12

Smart Images

  • Figure CN2026094572_12112026_PF_FP_ABST
    Figure CN2026094572_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A double-stranded siRNA inhibiting HSD17B13 expression and a conjugate thereof. The double-stranded siRNA inhibiting HSD17B13 expression comprises a sense strand and an antisense strand. The antisense strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides in the sequence shown in SEQ ID NO: 1; or the antisense strand comprises at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides in the sequence shown in SEQ ID NO: 3. One or more nucleotide residues in the nucleotide sequence of the sense strand and / or the antisense strand are replaced with r, which is represented by formula I. The siRNA has good inhibitory activity against HSD17B13 mRNA in vitro or in vivo.
Need to check novelty before this filing date? Find Prior Art